What is Claimed Is:

1. A lyophilate comprising (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate.

2. The lyophilate of claim 1 further comprising a stabilizing agent.

3. The lyophilate of claim 2, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/stabilizing agent weight ratio is about 10 to about 0.1.

4. The lyophilate of claim 3, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/stabilizing agent weight ratio is about 5 to about 0.25.

5. The lyophilate of claim 4, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/stabilizing agent weight ratio is about 0.67.

6. The lyophilate of any one of claims 2-5, wherein the stabilizing agent is polyvinylpyrrolidone.

7. The lyophilate of any one of claims 1-6 further comprising a buffering agent.

8. The lyophilate of claim 7, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/buffering agent weight ratio is about 20 to about 0.5.

9. The lyophilate of claim 8, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/buffering agent weight ratio is about 15 to about 2.

10. The lyophilate of claim 9, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/buffering agent weight ratio is about 6.5.

11. The lyophilate of any one of claims 7-10, wherein buffering agent is L-histidine.

12. The lyophilate of claim 1 comprising about 42 mg of (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate.

13. The lyophilate of claim 12 further comprising about 63 mg of polyvinylpyrrolidone.

14. The lyophilate of claims 12 or 13 further comprising about 6.5 mg of L-histidine.

15. A pharmaceutical composition comprising the lyophilate of any one of claims 1-14, wherein the lyophilate is reconstituted in a solvent.

16. The pharmaceutical composition of claim 15, wherein the solvent comprises ethanol and water.

17. The pharmaceutical composition of claim 16, wherein the solvent comprises about 40% to about 60% ethanol and about 60% to about 40% water.

18. The pharmaceutical composition of claim 17, wherein the solvent comprises about 45% to about 55% ethanol and about 55% to about 45% water.

19. The pharmaceutical composition of claim 18, wherein the solvent consists of about 50% ethanol and about 50% water.

20. The pharmaceutical composition of any one of claims 15-19, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate concentration is about 10 mg/mL.

21. A pharmaceutical formulation comprising the pharmaceutical composition of any one of claims 15-20 and a diluent.

22. The pharmaceutical formulation of claim 20, wherein the diluent is normal saline.

23. The pharmaceutical formulation of claim 22, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate concentration is about 0.012 to about 0.24 mg/mL.

24. A method for treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical formulation of any one of claims 20-23 to the subject.

25. The method of claim 24, wherein the pharmaceutical formulation is administered intravenously to the subject.

26. The method of claims 24 or 25 further comprising administering an optional therapeutic agent to the subject.

27. A method of making the lyophilate of any one of claims 1-14, the method comprising:

(i) preparing a pre-lyophilization solution comprising (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate and water;

(ii) cooling the pre-lyophilization solution until it is frozen or partially frozen; and

(iii) applying a vacuum to the frozen or partially frozen pre-lyophilization solution to give the lyophilate.

28. The method of claim 27, wherein the pre-lyophilization solution further comprises ethanol.

29. The method of claims 27 or 28, wherein the pre-lyophilization solution further comprises t-butanol.

30. A method of making the lyophilate of any one of claims 1-14, the method comprising:

(i) dissolving Compound 1 in a mixture of t-butanol, ethanol, and water at a temperature of about 25 ºC to about 35 ºC to give a pre-lyophilization solution;

(ii) cooling the pre-lyophilization solution until it is frozen or partially frozen; and

(iii) applying a vacuum to the frozen or partially frozen pre-lyophilization solution to give the lyophilate.

31. The method of any one of claims 27-30, wherein the pre-lyophilization solution further comprises polyvinylpyrrolidone.

32. The method of any one of claims 27-31, wherein the pre-lyophilization solution further comprises L-histidine.

33. The method of any one of claims 27-32, wherein the concentration of (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate in the pre-lyophilization solution is about 10 mg/mL.

34. A method of making the pharmaceutical composition of claim 15, the method comprising dissolving the lyophilate in a solvent.

35. The method of claim 34, wherein the solvent comprises water and ethanol.

36. A method of making the pharmaceutical formulation of claim 21, the method comprising admixing the pharmaceutical composition with a diluent.

37. The method of claim 36, wherein the diluent is normal saline.

38. A kit comprising the lyophilate of any one of claims 1-14 packaged as single unit dose in a vial.

39. The kit of claim 38 for the treatment of cancer in a subject in need thereof.

40. The kit of claims 38 or 39 further comprising instructions for reconstituting the lyophilate in a solvent to give a pharmaceutical composition.

41. The kit of any one of claims 38-40 further comprising instructions for admixing the pharmaceutical composition with a diluent to give a pharmaceutical formulation.

42. The kit of any one of claims 38-41 further comprising instructions for administering the pharmaceutical formulation to the subject.